Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337491 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab +/- Bevacizumab for Recurrent GBM
A Phase 2 study of Glioblastoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 8
- Study locations
NCT02337491 is a Phase 2 study of Glioblastoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 80 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (27% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT02337491, a Phase 2 study of Glioblastoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 8
- Study locations
Study Summary
In this research study, the investigators are looking to determine the effectiveness of Pembrolizumab (MK-3475) when given with bevacizumab or when given alone for the treatment of recurrent glioblastoma multiforme (GBM). This study will also test the safety and tolerability of Pembrolizumab (MK-3475) when given alone or with bevacizumab.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Bevacizumab
Study Locations (8)
California
- University of California, Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer - New York
North Carolina
- Duke University Medical Center - Durham
Texas
- UT, MD Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-02-09 |
| Est. Completion | 2020-09-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02337491
The ClinicalTrials.gov registry entry for NCT02337491 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (27% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02337491 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT02337491 about?
NCT02337491 is a clinical study titled "Pembrolizumab +/- Bevacizumab for Recurrent GBM". In this research study, the investigators are looking to determine the effectiveness of Pembrolizumab (MK-3475) when given with bevacizumab or when given alone for the treatment of recurrent glioblastoma multiforme (GBM). This study will also test the safety and tolerability of Pembrolizumab (MK-347...
What is the current status of trial NCT02337491?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2015-02-09. Estimated completion is 2020-09-14.
What conditions does trial NCT02337491 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02337491?
The interventions under investigation include: Pembrolizumab (DRUG), Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT02337491?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02337491 being conducted?
This trial has 8 study locations across California, Massachusetts, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.